Search results
Results from the WOW.Com Content Network
The median survival after TACE is 26–40 months with a tumor response rate of approximately 52%. [6] Combining TACE with systemic therapy (sorafenib or brivanib) does not improve survival. [6] The risk of death after transarterial treatments, including TACE, is about 1%, usually due to liver failure. [6]
The most frequent liver cancer, accounting for approximately 75% of all primary liver cancers, is hepatocellular carcinoma (HCC). [15] HCC is a cancer formed by liver cells, known as hepatocytes, that become malignant. In terms of cancer deaths, worldwide HCC is considered the 3rd most common cause of cancer mortalities. [16]
The survival rate for FLC largely depends on whether (and to what degree) the cancer has metastasized, i.e. spread to the lymph nodes or other organs. Distant spread (metastases), significantly reduces the median survival rate. [19] Five-year survival rates vary between 40 and 90%. [19]
In a randomized, double-blind, phase II trial combining sorafenib with doxorubicin, the median time to progression was not significantly delayed compared with doxorubicin alone in patients with advanced hepatocellular carcinoma. Median durations of overall survival and progression-free survival were significantly longer in patients receiving ...
In a series of 322 patients undergoing bland embolization for HCC with a median follow-up of 20 months, 1-, 2-, and 3- year overall survival rates were 66%, 46% and 33% respectively. When patients with extra-hepatic disease or portal vein involvement were excluded, overall 1-, 2- and 3-year survival rates rose to 84%, 66% and 51%, and median ...
Several types of cancer are associated with high survival rates, including breast, prostate, testicular and colon cancer. Brain and pancreatic cancers have much lower median survival rates which have not improved as dramatically over the last forty years. [4] Indeed, pancreatic cancer has one of the worst survival rates of all cancers.
The median survival after the development of hepatic encephalopathy is 0.9 years. [59] ... Hepatocellular carcinoma is the most common primary liver cancer, ...
Hepatocellular adenomas (also called hepatocellular adenoma) are rare benign liver tumors made up of hepatocytes, [2] with estimates indicating hepatocellular adenomas make up 2% of liver tumors. [7] They are most common in women using contraceptives or hormone replacement therapies containing estrogen , women who are pregnant, or people mis ...